Contact:
4008465777
About Us
Tonghua Dongbao's Entire Insulin Lineup Secures Category A in the VBP Program, With Two Types Categorized as A1
On April 23, 2024, China's Joint Procurement Office (JPO) announced the preliminarily selected bids from a continued round of the national volume-based procurement (VBP) program for insulin. This ...
Tonghua Dongbao releases 2023 sustainability report
On March 28, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2023 sustainability report. The report disclosed ...
Tonghua Dongbao achieves record product sales in 2023, driving performance growth
Performance summaryIn 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") reported:RMB 3.075 billion in revenue, an incre...
Tonghua Dongbao: First Chinese-made dual-target inhibitor for gout (THDBH151 Tablets) meets primary endpoint in phase I clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a Phase I pivotal ...
Tonghua Dongbao announces NMPA acceptance of clinical trial application for dual GLP-1/GIP receptor agonist (THDBH120 injection) intended for weight loss indications
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the "Company" or "Tonghua Dongbao") received ...
Tonghua Dongbao: novel URAT1 inhibitor (THDBH130 Tablets) meets primary endpoint in phase IIa clinical trial
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao"), recently completed a multicenter, ran...